November 1, 2009
This article reviews the 10 newly improved or investigational agents evaluated in this year's "Focus on" column and includes an update on the regulatory status of each drug.
 |
November 1, 2009
By:Traci C. Brooks, PharmD, Mark Burlingame, PharmD, BCPS, Muriel Burk, PharmD, Kathy Tortorice, PharmD, BCPS, Diane Dong, BSN, MS, Peter A. Glassman, MBBS, MSc, Jennie A. Lynch, PharmD, Chester B. Good, MD, MPH, Holly S. Rickman, MS, PharmD, Melanie Claborn, PharmD, Duva Appleman, MD, William Jones, MS, FASHP, VACO, Lanita Shaverd, PharmD
In August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.
|
October 1, 2009
By:Steven B. Russek, RPh
Specialty pharmacies are uniquely positioned to play a key role in the implementation of Risk Evaluation and Mitigation Strategies (REMS).
|
October 1, 2009
By:Brett Feret, PharmD
Fampridine-SR is a sustained-release oral medication that is pending FDA approval for the symptomatic treatment of multiple sclerosis (MS).
|
September 1, 2009
By:Olivia J. Phung, PharmD, Craig I. Coleman, PharmD
Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
|
August 1, 2009
By:Teresa K. Hoffmann, PharmD, CACP, CDE, CLS, Mary Ann Tucker, PharmD, Debra L. Parker, PharmD, CACP, CDE, CLS
This review discusses emerging risk factors for CVD, including hs-CRP, lipoprotein(a), homocysteine, fibrinogen, homocysteine, and coronary artery calcification.
|
| 
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.